Metanovas Biotech

What Metanovas Biotech does

MetaNovas Biotech is an AI-native biotechnology company founded in 2021 and headquartered in Mountain View, California, that designs bioactive ingredients, medical materials, and functional polymers using a proprietary Agentic AI platform. Its core technology stack centers on the MetAmigo system, a molecular language generation model covering over 10^60 chemical spaces with a first recommendation success rate exceeding 60%, and a fleet of 10+ autonomous AI agents (Orphic R&D, MetaClaw Brand OS, brand-director, competitor-analysis, ingredient-screening, content-generation, brand-sentiment-monitor) that operate 24/7. The company has built specialized sub-platforms including MetaPep AI for bioactive peptide discovery (with three commercial peptides — MetaTlr, MetaScalp, MetaCono — each with specific clinical efficacy claims) and, via its associated Metanova Labs entity, a decentralized virtual screening proof-of-concept on the Bittensor network that has screened 4.8 million molecules across 7,000 protein targets.

MetaNovas serves enterprise customers in the personal care, consumer health, and cosmetic/medical beauty verticals, with AI-designed molecules already landed in product lines of leading brands in China and the United States. Unilever has publicly expressed interest in its molecular ingredients. The company goes to market through a direct enterprise sales motion, targeting brand-side R&D and innovation teams in the global personal care value chain, and supplements this with conference presence (in-cosmetics Global 2025), sponsored media (CTO Lun Yu video interview), and earned media coverage in China-based biotech and cosmetics publications.

The business model is anchored on licensing and royalty arrangements for AI-designed molecular ingredients, augmented by platform-licensing of the MetAmigo agentic system to enterprise customers. MetaNovas is venture-backed across multiple rounds (a confirmed $10M round in March 2022 led by Redhill Capital and Sinopharm Capital, plus subsequent A, A+, and A++ rounds led or participated in by Hillhouse Capital/Ventures, Baoding Ventures, Fuhua Capital, Kangaroo Mama Group, GRC SinoGreen Fund, and Yayan Biotech). Leadership comprises co-founder and CEO Meijie Wang and CTO Lun Yu. The company claims the fastest bioactive raw material development cycle in the industry at 12 months from concept to human efficacy testing.

Name

Metanovas Biotech

Legal name

MetaNovas

Website

https://metanovas.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

MetaNovas Biotech is an AI-native biotech company that designs bioactive ingredients, medical materials, and functional polymers via its proprietary Agentic AI platform (MetAmigo) and molecular language generation model, licensing outputs to leading personal care and consumer health brands in China and the United States.

Ownership category

akta.pro rank

Product category

AI-Driven Bioactive Ingredient Design

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI molecular design
• Bioactive peptide discovery
• Agentic AI R&D
• AI-designed ingredients
• Cosmetic biotechnology

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. AI-Designed Molecular Ingredients: MetaNovas generates revenue by designing and commercializing AI-developed bioactive ingredients, medical materials, and functional polymers for consumer health brands. The company lands AI-designed molecules into product lines of leading brands in China and the United States, suggesting a B2B ingredients/supply model.
2. Technology Platform Licensing: The company licenses its Agentic AI platform capabilities (MetAmigo) and AI-designed molecules to enterprise customers in medical devices and cosmetic/medical beauty sectors, enabling commercial-scale transition from AI-designed to AI-implemented molecules.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

MetaNovas Biotech develops AI-designed bioactive ingredients, medical materials, and functional polymers using its Agentic AI platform (MetAmigo) and molecular language generation model. The company licenses these AI-designed molecules to enterprise personal care and health brands for use in cosmetic, skincare, scalp care, and medical beauty products, compressing bioactive raw material development timelines to 12 months from concept to human efficacy testing.

Product overview

MetaNovas Biotech offers an integrated AI-powered platform ecosystem combining Agentic AI systems for autonomous R&D and brand operations. The core offerings include: (1) MetAmigo - the Agentic AI system for molecular R&D in medical devices and cosmetic/medical beauty products; (2) MetaPep AI - specialized platform for discovering bioactive peptides for skin and scalp care; (3) Orphic R&D - ingredient-screening agent for new material discovery; (4) MetaClaw Brand OS - brand management operating system with content generation and sentiment monitoring; and (5) a proprietary molecular language generation model covering over 10^60 chemical spaces. The platform enables the fastest bioactive raw material to progress from concept to human efficacy testing within 12 months, with commercial-scale deployment of AI-designed molecules.

Differentiator

Problem solved

Functional benefit

Brands

• MetaPep: AI platform for discovering and developing bioactive peptides for skin and scalp care applications
• MetAmigo
• Orphic
• MetaClaw
• MetaTlr
• MetaScalp
• MetaCono

Products and services

• MetAmigo Agentic AI system for advancing molecular research and development in medical devices and cosmetic medical beauty products, enabling commercial-scale transition from AI-designed to AI-implemented molecules. Targeted at enterprise personal care and health brands.
• MetaPep AI Platform AI platform for discovering and developing bioactive peptides for skin and scalp care applications, featuring novel peptides MetaTlr (senomorphic), MetaScalp (anti-dandruff), and MetaCono (anti-aging). Targeted at personal care brands.
• Molecular Language Generation Model Proprietary AI model covering over 10^60 chemical spaces with first recommendation success rate exceeding 60%, enabling rapid design of new bioactive ingredients, medical materials, and functional polymers for enterprise customers.
• MetaTlr Peptide Senomorphic bioactive peptide for skin care that reduces inflammatory markers and UV damage. Designed for use in personal care and cosmetic formulations by enterprise brands.
• MetaScalp Peptide Anti-dandruff bioactive peptide for scalp care with clinical results within 28 days. Designed for use in scalp care formulations by enterprise brands.
• MetaCono Peptide Bicyclic anti-aging bioactive peptide that reduces wrinkles within 30 minutes. Designed for use in anti-aging cosmetic formulations by enterprise brands.

Quantifiable outcome

• Reduces bioactive raw material development timeline from industry-average multi-year cycles to 12 months (concept to human efficacy testing)
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Amai Proteins: AI-designed food and consumer health proteins. Comparable to MetaNovas on computational protein/peptide design applied to consumer products rather than pharma.
• Cradle Bio: AI platform for protein engineering and design across pharma and industrial biotech. Comparable on AI-enabled protein/biologic design, though focused more on R&D tooling than finished ingredients.
• Anagenex: AI-driven small molecule discovery combining DNA-encoded libraries with machine learning. Comparable as an emerging AI molecular design platform pursuing novel bioactive compounds.
• Generate Biomedicines: Generative biology platform for programmable protein therapeutics. Comparable to MetaNovas' AI-designed biologic discovery but focused on therapeutic rather than cosmetic applications.

Direct peers

• Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Directly comparable to MetaNovas' use of molecular language models to design bioactive molecules at commercial scale.
• Geltor: Designer protein company producing animal-free bioactive proteins for personal care and beauty. Directly comparable to MetaNovas MetaPep peptide line in AI-designed bioactive ingredients for cosmetics.
• Schrödinger: Computational chemistry and molecular simulation platform used for drug and materials discovery. Directly comparable to MetaNovas' molecular language generation model and virtual screening capabilities.
• Atomwise: AI-driven small molecule discovery using structure-based design and virtual screening. Comparable as a direct AI molecular design competitor pursuing bioactive compound discovery.
• XtalPi: AI-powered drug discovery combining physics-based modeling and machine learning, with strong China presence. Closely comparable to MetaNovas on AI molecular design and dual US/China market reach.
• Recursion Pharmaceuticals: AI/ML drug discovery platform combining high-throughput biology with computational models. Comparable to MetaNovas' agentic AI approach to high-throughput molecule generation and screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/metanovas-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metanovas Biotech